WikiDoc Resources for Liquid breathing |
Articles |
---|
Most recent articles on Liquid breathing Most cited articles on Liquid breathing |
Media |
Powerpoint slides on Liquid breathing |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Liquid breathing at Clinical Trials.gov Trial results on Liquid breathing Clinical Trials on Liquid breathing at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Liquid breathing NICE Guidance on Liquid breathing
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Liquid breathing Discussion groups on Liquid breathing Patient Handouts on Liquid breathing Directions to Hospitals Treating Liquid breathing Risk calculators and risk factors for Liquid breathing
|
Healthcare Provider Resources |
Causes & Risk Factors for Liquid breathing |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Liquid breathing is a form of respiration in which a normally air-breathing organism breathes an oxygen rich liquid (usually a perfluorocarbon), rather than breathing air. It is used for medical treatment and could some day find use in deep diving and space travel. Liquid breathing is sometimes called fluid breathing, but this can be confusing because both liquids and gases can be called fluids.
Despite recent advances in liquid ventilation, a standard mode of application of perfluorocarbon (PFC) has not been established yet.
Although Total Liquid Ventilation (TLV) with completely liquid filled lungs is beneficial, the necessity for a liquid filled tube system that contains pumps and heater and membrane oxygenator to deliver and remove tidal volume aliquots of conditioned perfluorocarbon to the lungs is of great disadvantage.
In contrast, Partial Liquid Ventilation (PLV) can be applied using standard ventilators connected with gas filled standard respirator systems, delivering tidal volumes of oxygen-air mixture to lungs which are partly filled with perfluorocarbon (typically to about functional residual capacity, which is about 40% of total lung capacity).
The influence of PLV on oxygenation, carbon dioxide removal and lung mechanics has been investigated in several animal studies using different models of lung injury. Clinical applications of PLV have been reported in patients with Acute Respiratory Distress Syndrome (ARDS), meconium aspiration syndrome, congenital diaphragmatic hernia and Respiratory Distress Syndrome (RDS) of neonates. PLV requires extreme respiratory care, because the ventilatory setting is determined by the perfluorocarbon filled lung. Profound expertise is mandatory to perform and maintain filling of the lung with perfluorocarbon to Functional Residual Capacity (FRC). Disruption of PLV immediately deteriorates gas exchange. Incomplete filling of the lung has been shown to be less effective than filling the lung to functional residual capacity volume. Severe adverse events affecting gas exchange and pulmonary circulation limit the use of PLV.
New application modes for PFC have been developed[1].
Vaporization of perfluorohexane with two anesthetic vaporizers calibrated for perfluorohexane has been shown to improve gas exchange in oleic acid induced lung injury in sheep [2]. Predominantly PFCs with high vapor pressure are suitable for vaporization.
With aerosolized perfluorooctane, significant improvement of oxygenation and pulmonary mechanics was shown in adult sheep with oleic acid-induced lung injury. In surfactant-depleted piglets, persistent improvement of gas exchange and lung mechanics was demonstrated with Aerosol-PFC [3]. The aerosol device is of decisive importance for the efficacy of PFC aerosolization, as aerosolization of PF5080 (a less purified FC77) has been shown to be ineffective using a different aerosol device in surfactant-depleted rabbits (Kelly). Partial liquid ventilation and Aerosol-PFC reduced pulmonary inflammatory response [4].
In diving, the pressure inside the lungs must effectively equal the pressure outside the body, otherwise the lungs collapse. Mathematically speaking, if the diver is f feet (or m meters) deep, and the air pressure at the water surface is p bar (usually p = 1, but less at high-altitude lakes such as Lake Titicaca), he must breathe fluid at a pressure of f/33+p = m/10+p bar.
Since external and internal pressures must be equal, the required gas pressure increases with depth to match the increased external water pressure, rising to around 13 bar at 400 feet (120m), and around 500 bar on the oceans' abyssal plains. These high pressures may have adverse effects on the body, especially when quickly released (as in a too-rapid return to the surface), including air emboli and decompression sickness (colloquially known as "the bends"). (Diving mammals, as well as free-diving humans who dive to great depths on a single breath, have little or no problem with decompression sickness despite their rapid return to the surface, since a single breath of gas does not contain enough total nitrogen to cause tissue bubbles on decompression. In very deep-diving mammals and deep free-diving humans, the lungs almost completely collapse).
One solution is a rigid articulated diving suit, but these are bulky and clumsy. A more moderate option to deal with narcosis is to breathe heliox or trimix, in which some or all of the nitrogen is replaced by helium. However, this option does not deal with the problem of bubbles and decompression sickness, because helium dissolves in tissues and causes bubbles when pressures are released, just like nitrogen does.
Liquid breathing provides a third option. With liquid in the lungs, the pressure within the diver's lungs could accommodate changes in the pressure of the surrounding water without the huge gas partial pressure exposures required when the lungs are filled with gas. Liquid breathing would not result in the saturation of body tissues with high pressure nitrogen or helium that occurs with the use of non-liquids, thus would reduce or remove the need for slow decompression. (This technology was dramatized in James Cameron's 1989 film The Abyss.)
A significant problem, however, arises from the required density of the liquid and the corresponding reduction in its ability to remove CO2. All uses of liquid breathing for diving must involve total liquid ventilation (see above). Total liquid ventilation, however, has difficulty moving enough fluid to carry away CO2, because no matter how great the total pressure is, the amount of partial CO2 gas pressure available to dissolve CO2 into the breathing liquid can never be much more than the pressure at which CO2 exists in the blood (about 40 mm of mercury (Torr)).
At these pressures, most fluorocarbon liquids require about 70 mL/kg minute-ventilation volumes of liquid (about 5 L/min for a 70 kg adult) to remove enough CO2 for normal resting metabolism.[5] This is a great deal of fluid to move, particularly as it is about 1.8 times as dense as water; any activity on the diver's part which increases CO2 production would increase this figure, which is at the limits of realistic flow rates in liquid breathing.[6][7] It seems unlikely that a person would move 10 liters/min of fluorocarbon liquid without assistance from a mechanical ventilator, so "free breathing" may be unlikely.
The first medical use of liquid breathing was treatment of premature babies and adults with acute respiratory distress syndrome (ARDS) in the 1990s. Liquid breathing was used in clinical trials after the development by Alliance Pharmaceuticals of the fluorochemical perfluorooctyl bromide, or perflubron for short. Useful as an emulsified blood substitute and for liquid ventilation, perflubron (under Alliance Pharmaceutical's brand name LiquiVent) is poured directly into the lungs of patients with acute respiratory failure (caused by infection, severe burns, inhalation of toxic substances, and premature birth), whose air sacs have collapsed. Once inside the lungs, perflubron enables collapsed alveoli (air sacs) to open and permits a more efficient transport of oxygen and carbon dioxide.
Clinical trials with premature infants, children and adults were conducted. Since the safety of the procedure and the effectiveness were apparent from an early stage, the US Food and Drug Administration (FDA) gave the product "fast track" status (meaning an accelerated review of the product, designed to get it to the public as quickly as is safely possible) due to its life-saving potential. Clinical trials showed that using perflubron with ordinary ventilators improved outcomes as much as using high frequency oscillating ventilation (HFOV). But because perflubron was not better than HFOV, the FDA did not approve perflubron, and Alliance is no longer pursuing the partial liquid ventilation application. Whether perflubron would improve outcomes when used with HFOV remains an open question.
In 1996 Mike Darwin and Dr. Steven B. Harris proposed using cold liquid ventilation with perfluorocarbon to quickly lower the body temperature of victims of cardiac arrest and other brain trauma to allow the brain to better recover.[8] The technology came to be called gas/liquid ventilation (GLV), and was shown able to achieve a cooling rate of 0.5 degrees Celsius per minute in large animals.[9] It has not yet been tried in humans.
Liquid immersion provides a way to reduce the physical stress of G forces. Forces applied to fluids are distributed as omnidirectional pressures. Because liquids are (virtually) incompressible, they do not change density under high acceleration such as performed in aerial maneuvers or space travel. A person immersed in liquid of the same density as tissue has acceleration forces distributed around the body, rather than applied at a single point such as a seat or harness straps. This principle is used in a new type of G-suit called the Libelle G-suit, which allows aircraft pilots to remain conscious and functioning at more than 10 G acceleration by surrounding them with water in a rigid suit.
Acceleration protection by liquid immersion is limited by the differential density of body tissues and immersion fluid, limiting the utility of this method to about 15 to 20 G[10] Extending acceleration protection beyond 20 G requires filling the lungs with fluid of density similar to water. An astronaut totally immersed in liquid, with liquid inside all body cavities, will feel little effect from extreme G forces because the forces on a liquid are distributed equally, and in all directions simultaneously. However effects will be felt because of density differences between different body tissues, so an upper acceleration limit still exists.
Around 1970, liquid breathing found its way into television, in alien spacesuits in the Gerry Anderson UFO series, which enabled a spaceman to withstand extreme acceleration forces.
Author Joe Haldeman, in his science fiction novel The Forever War, describes fluid being introduced into all 7 natural orifices in the human body, and one surgically-added connection, through which the thoracic cavity would be filled and drained. In such a situation, the fluid in the lungs would have to be pumped in and out to provide an inspiration/expiration cycle (total liquid ventilation). Alternatively blood could be oxygenated extracorporeally while lungs remained full of passive fluid, although this is not really liquid breathing.
Liquid breathing for acceleration protection may never be practical because of the difficulty of finding a suitable breathing medium of similar density to water that is compatible with lung tissue. Perfluorocarbon fluids are twice as dense as water, hence unsuitable for this application.
Taken, with permission, from: Fluid Breathing, and afterwards edited.
*seven days season 1 episode 13*